GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aspen Pharmacare Holdings Ltd (OTCPK:APNHY) » Definitions » Valuation Rank

Aspen Pharmacare Holdings (Aspen Pharmacare Holdings) Valuation Rank


View and export this data going back to 2009. Start your Free Trial

What is Aspen Pharmacare Holdings Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


Aspen Pharmacare Holdings Valuation Rank Related Terms

Thank you for viewing the detailed overview of Aspen Pharmacare Holdings's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Aspen Pharmacare Holdings (Aspen Pharmacare Holdings) Business Description

Traded in Other Exchanges
Address
Douglas Saunders Drive, Aspen Place, 9 Rydall Vale Park, La Lucia Ridge, Durban, NL, ZAF
Aspen Pharmacare Holdings Ltd is a specialty pharmaceutical company with a commercial footprint covering more than 50 countries and complex manufacturing capabilities in both API and finished dose form. The company focuses on a broad range of post-patent, branded medicines and domestic brands spanning many therapeutic areas. The company has four business segments such as Active Pharmaceutical Ingredients (API) - this segment includes the API Chemicals business and non-heparin biochemical API business, Heparin - this segment includes the full value chain contribution from all heparin containing products including API and Finished Dose. Form (FDF) sales Key products include the Fraxiparine and MonoEmbolex heparin containing FDF products and FDF Steriles segment.